Effect of 'high-dose' amikacin in children.
17 children with serious infections were treated for an average period of 9.5 days with 420 mg/m2/dose of amikacin every 8 h. The nephrotoxicity and ototoxicity of this 'high-dose' regimen was studied. None of the children had evidence of nephrotoxicity. Of 9 children who could be clearly evaluated, 1 child experienced a delayed transient auditory dysfunction. 1 child experienced delayed serious deafness, but was receiving other ototoxic drugs. Despite the fact that the doses averaged 54.1 mg/kg/day, 5 children in our series had peak concentrations lower than that recommended for adults with serious infection.
D000293:Adolescent; D000583:Amikacin / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D003404:Creatinine / Q000097:blood; D003638:Deafness / Q000139:chemically induced; D006309:Hearing / Q000187:drug effects; D006312:Hearing Loss, Bilateral / Q000139:chemically induced; D006801:Humans; D007223:Infant; D007612:Kanamycin / Q000031:analogs & derivatives*; D007668:Kidney / Q000187:drug effects; D013997:Time Factors
D007612:Kanamycin; D000583:Amikacin; D003404:Creatinine